메뉴 건너뛰기




Volumn 76, Issue 1, 2009, Pages 39-43

Infliximab for treating axial spondylarthropathy in everyday practice

Author keywords

Ankylosing spondylitis; Infliximab; Spondylarthropathy; TNF antagonists

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

EID: 58249091396     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.07.012     Document Type: Article
Times cited : (8)

References (22)
  • 1
    • 0034715977 scopus 로고    scopus 로고
    • Crohn's disease associated with spondylarthropathy: effect of TNFα blockade with infliximab on articular symptoms
    • Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondylarthropathy: effect of TNFα blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
    • (2000) Lancet , vol.356 , pp. 1821-1822
    • Van den Bosch, F.1    Kruithof, E.2    De Vos, M.3
  • 2
    • 0028903218 scopus 로고
    • Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
    • Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
    • (1995) Arthritis Rheum , vol.38 , pp. 499-505
    • Braun, J.1    Bollow, M.2    Neure, L.3
  • 3
    • 0021272107 scopus 로고
    • Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New-York criteria
    • Van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New-York criteria. Arthritis Rheum 27 (1984) 361-368
    • (1984) Arthritis Rheum , vol.27 , pp. 361-368
    • Van der Linden, S.1    Valkenburg, H.A.2    Cats, A.3
  • 4
    • 0036852331 scopus 로고    scopus 로고
    • Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open-label study
    • Breban M., Vignon E., Claudepierre P., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open-label study. Rheumatology (Oxford) 41 (2002) 1280-1285
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1280-1285
    • Breban, M.1    Vignon, E.2    Claudepierre, P.3
  • 5
    • 0036188187 scopus 로고    scopus 로고
    • Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy
    • Van den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46 (2002) 755-765
    • (2002) Arthritis Rheum , vol.46 , pp. 755-765
    • Van den Bosch, F.1    Kruithof, E.2    Baeten, D.3
  • 6
    • 0345490895 scopus 로고    scopus 로고
    • Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study
    • Temekonidis T.I., Alamanos Y., Nikas S., et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62 (2003) 1218-1220
    • (2003) Ann Rheum Dis , vol.62 , pp. 1218-1220
    • Temekonidis, T.I.1    Alamanos, Y.2    Nikas, S.3
  • 7
    • 0034094123 scopus 로고    scopus 로고
    • Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
    • Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43 (2000) 1346-1352
    • (2000) Arthritis Rheum , vol.43 , pp. 1346-1352
    • Brandt, J.1    Haibel, H.2    Cornely, D.3
  • 8
    • 0037029430 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    • Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
    • (2002) Lancet , vol.359 , pp. 1187-1193
    • Braun, J.1    Brandt, J.2    Listing, J.3
  • 9
    • 0042072982 scopus 로고    scopus 로고
    • Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
    • Braun J., Brandt J., Listing J., et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48 (2003) 2224-2233
    • (2003) Arthritis Rheum , vol.48 , pp. 2224-2233
    • Braun, J.1    Brandt, J.2    Listing, J.3
  • 10
    • 0038423033 scopus 로고    scopus 로고
    • for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis
    • Braun J., Pham T., Sieper J., et al. for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
    • (2003) Ann Rheum Dis , vol.62 , pp. 817-824
    • Braun, J.1    Pham, T.2    Sieper, J.3
  • 11
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
    • Garrett S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21 (1994) 2286-2291
    • (1994) J Rheumatol , vol.21 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3
  • 12
    • 0034130272 scopus 로고    scopus 로고
    • Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study
    • Van den Bosch F., Kruithof E., Baeten D., et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59 (2000) 428-433
    • (2000) Ann Rheum Dis , vol.59 , pp. 428-433
    • Van den Bosch, F.1    Kruithof, E.2    Baeten, D.3
  • 14
    • 0026003027 scopus 로고
    • The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
    • Dougados M., Van den Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
    • (1991) Arthritis Rheum , vol.34 , pp. 1218-1227
    • Dougados, M.1    Van den Linden, S.2    Juhlin, R.3
  • 15
    • 0028579768 scopus 로고
    • A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index
    • Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21 (1994) 2281-2285
    • (1994) J Rheumatol , vol.21 , pp. 2281-2285
    • Calin, A.1    Garrett, S.2    Whitelock, H.3
  • 16
    • 0042508748 scopus 로고    scopus 로고
    • for the ASAS Working Group: initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group
    • Pham T., Van der Heijde D., Calin A., et al. for the ASAS Working Group: initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 62 (2003) 812-816
    • (2003) Ann Rheum Dis , vol.62 , pp. 812-816
    • Pham, T.1    Van der Heijde, D.2    Calin, A.3
  • 17
    • 33144469246 scopus 로고    scopus 로고
    • First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
    • Braun J., Davis J., Dougados M., et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 316-320
    • (2006) Ann Rheum Dis , vol.65 , pp. 316-320
    • Braun, J.1    Davis, J.2    Dougados, M.3
  • 18
    • 19544388586 scopus 로고    scopus 로고
    • Infliximab treatment in ankylosing spondylitis: an observational study
    • Nikas S.N., Alamanos Y., Voulgari P.V., et al. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64 (2005) 940-942
    • (2005) Ann Rheum Dis , vol.64 , pp. 940-942
    • Nikas, S.N.1    Alamanos, Y.2    Voulgari, P.V.3
  • 19
    • 36849016433 scopus 로고    scopus 로고
    • Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French Society of Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
    • Pham T., Fautrel B., Dernis E., et al. Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French Society of Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74 (2007) 638-646
    • (2007) Joint Bone Spine , vol.74 , pp. 638-646
    • Pham, T.1    Fautrel, B.2    Dernis, E.3
  • 20
    • 34248137517 scopus 로고    scopus 로고
    • Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial
    • [abstract]
    • Haibel H., Rudwaleit M., Heldmann F., et al. Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial. [abstract]. Arthritis Rheum 54 Suppl (2006) L24
    • (2006) Arthritis Rheum , vol.54 , Issue.SUPPL
    • Haibel, H.1    Rudwaleit, M.2    Heldmann, F.3
  • 21
    • 58149194663 scopus 로고    scopus 로고
    • Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: 52-week results of a randomized controlled trial and open-label extension
    • (abstract 753)
    • Haibel H., Rudwaleit M., Amtenbrink A., et al. Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: 52-week results of a randomized controlled trial and open-label extension. Arthritis Rheum 56 9 Suppl. (2007) S320-S321 (abstract 753)
    • (2007) Arthritis Rheum , vol.56 , Issue.9 SUPPL
    • Haibel, H.1    Rudwaleit, M.2    Amtenbrink, A.3
  • 22
    • 58149189908 scopus 로고    scopus 로고
    • A randomized controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis
    • Barkham N., Keen H., Coates L., et al. A randomized controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis. Arthritis Rheum 56 Suppl (2006) L11
    • (2006) Arthritis Rheum , vol.56 , Issue.SUPPL
    • Barkham, N.1    Keen, H.2    Coates, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.